Sorafenib Plus Toripalimab for Unresectable HCC With Portal Vein Tumor Thrombus
An Exploratory Study of Sorafenib Plus Toripalimab for Unresectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombus
Sponsor: Sichuan University
Listed as NCT04069949, this PHASE1/PHASE2 trial focuses on Portal Vein Tumor Thrombus and Unresectable Hepatocellular Cancer and remains ongoing. Sponsored by Sichuan University, it has been updated 6 times since 2019, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE1/PHASE2
Status: Unknown Status → Unknown · Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Nov 2021 — Jul 2024 [monthly]
Unknown Status PHASE1_PHASE2
Status: Not Yet Recruiting → Unknown Status
-
Jan 2021 — Nov 2021 [monthly]
Not Yet Recruiting PHASE1_PHASE2
-
Nov 2019 — Jan 2021 [monthly]
Not Yet Recruiting PHASE1_PHASE2
▶ Show 1 earlier version
-
Sep 2019 — Nov 2019 [monthly]
Not Yet Recruiting PHASE1_PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Sichuan University
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
No location information available.